Payment overview · 2025
General Payments
$237.49
8 reported records · 8 companies
Healthcare provider profile · identity verified
Robert L Pugh, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MURRELLS INLET, SC · NPI 1407814791
Verified facts
What the public records show
CMS Open Payments records show Robert L Pugh, MD received $237.49 in general payments during 2025 across 8 reported records.
Novo Nordisk Inc accounted for 51.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $123.07 | 51.8% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.14 | 8.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.60 | 7.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.94 | 7.1% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $16.44 | 6.9% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16.06 | 6.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.95 | 6.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $11.29 | 4.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $237.49 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $123.07 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $21.14 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.60 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $17.60 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.94 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.94 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $16.44 | 1 | 2025 |
Source payment records
|
|||||
| Belbuca Normalized: belbuca |
Drug | Collegium Pharmaceutical, Inc. | $16.06 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.95 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.95 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $11.29 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
52 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 306 | 41 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 238 | 36 |
| Oxycodone Hcl | Oxycodone Hcl | 235 | 27 |
| Amlodipine Besylate | Amlodipine Besylate | 219 | 59 |
| Levothyroxine Sodium | Levothyroxine Sodium | 218 | 65 |
| Atorvastatin Calcium | Atorvastatin Calcium | 214 | 61 |
| Lorazepam | Lorazepam | 211 | 33 |
| Alprazolam | Alprazolam | 203 | 30 |
| Lisinopril | Lisinopril | 185 | 56 |
| Clonazepam | Clonazepam | 162 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 160 | 45 |
| Prednisone | Prednisone | 157 | 85 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 143 | 46 |
| Testosterone Cypionate | Testosterone Cypionate | 135 | 21 |
| Gabapentin | Gabapentin | 127 | 28 |
| Azithromycin | Azithromycin | 112 | 55 |
| Omeprazole | Omeprazole | 112 | 32 |
| Metformin Hcl | Metformin Hcl | 110 | 32 |
| Meloxicam | Meloxicam | 109 | 42 |
| Diazepam | Diazepam | 106 | 14 |
| Losartan Potassium | Losartan Potassium | 104 | 36 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 103 | 14 |
| Pantoprazole Sodium | Pantoprazole Sodium | 96 | 28 |
| Simvastatin | Simvastatin | 88 | 25 |
| Furosemide | Furosemide | 85 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 85 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 83 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 83 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 78 | 26 |
| Bupropion Xl | Bupropion Hcl | 76 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 75 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 73 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 72 | 23 |
| Trazodone Hcl | Trazodone Hcl | 72 | 21 |
| Methadone Hcl | Methadone Hcl | 69 | suppressed |
| Temazepam | Temazepam | 67 | 12 |
| Eliquis | Apixaban | 66 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 65 | 22 |
| Sertraline Hcl | Sertraline Hcl | 63 | 17 |
| Tramadol Hcl | Tramadol Hcl | 62 | 18 |
| Trulicity | Dulaglutide | 60 | suppressed |
| Allopurinol | Allopurinol | 59 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 56 | 16 |
| Potassium Chloride | Potassium Chloride | 56 | 13 |
| Synthroid | Levothyroxine Sodium | 52 | 12 |
| Famotidine | Famotidine | 51 | 17 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 51 | 35 |
| Morphine Sulfate Er | Morphine Sulfate | 49 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 47 | 13 |
| Glipizide | Glipizide | 41 | 12 |
| Doxepin Hcl | Doxepin Hcl | 40 | suppressed |
| Ozempic | Semaglutide | 40 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 39 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 39 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 39 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 38 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 38 | 11 |
| Celecoxib | Celecoxib | 35 | suppressed |
| Cephalexin | Cephalexin | 35 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Pregabalin | Pregabalin | 35 | 13 |
| Fluconazole | Fluconazole | 34 | 14 |
| Cefuroxime | Cefuroxime Axetil | 33 | 26 |
| Montelukast Sodium | Montelukast Sodium | 33 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 33 | suppressed |
| Oxycontin | Oxycodone Hcl | 32 | suppressed |
| Atenolol | Atenolol | 31 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 31 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 31 | suppressed |
| Carvedilol | Carvedilol | 30 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 21 |
| Levofloxacin | Levofloxacin | 27 | 21 |
| Ibuprofen | Ibuprofen | 26 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Sucralfate | Sucralfate | 26 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 25 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | suppressed |
| Fentanyl | Fentanyl | 23 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Gemfibrozil | Gemfibrozil | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Xtampza Er | Oxycodone Myristate | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Metolazone | Metolazone | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Finasteride | Finasteride | 17 | suppressed |
| Jardiance | Empagliflozin | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 16 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | 11 |
| Irbesartan | Irbesartan | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | suppressed |
| Indomethacin | Indomethacin | 13 | suppressed |
| Oxymorphone Hcl Er | Oxymorphone Hcl | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Dotti | Estradiol | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $237.49 · 8 records | Novo Nordisk Inc | AREXVY, Belbuca, CAPLYTA, GVOKE HYPOPEN, OTEZLA, Ozempic, QULIPTA, REPATHA, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error